Daiichi Sankyo (OTCMKTS:DSNKY) Releases FY 2026 Earnings Guidance

Daiichi Sankyo (OTCMKTS:DSNKY) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.870-0.870 for the period, compared to the consensus EPS estimate of 1.040. The company issued revenue guidance of $14.7 billion-$14.7 billion, compared to the consensus revenue estimate of $13.4 billion.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Daiichi Sankyo Stock Performance

Daiichi Sankyo stock traded down $2.09 on Friday, hitting $16.14. The company’s stock had a trading volume of 92,402 shares, compared to its average volume of 391,373. Daiichi Sankyo has a one year low of $14.98 and a one year high of $27.50. The firm has a market cap of $30.07 billion, a P/E ratio of 17.17, a price-to-earnings-growth ratio of 3.10 and a beta of -0.17. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18. The company has a fifty day moving average price of $16.52 and a 200-day moving average price of $17.74.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its earnings results on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.02). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities analysts anticipate that Daiichi Sankyo will post 0.96 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.